M3 Biotechnology, Inc.
M3 Biotechnology, Inc. is listed today as LeonaBio, Inc.: market value, financials and filings are on its company page.
Funding rounds
2 counted as startup funding. Open the number of investors for the round's details.
| Month | Raised | Raise | Size | Investors | Sold | Filing |
|---|---|---|---|---|---|---|
| May 2020 | $89 M | No. 2 | $50 to $250 million | equity, options | SEC | |
| Oct 2015 | $14 M | No. 1 | $10 to $50 million | equity | SEC |
Source: SEC Form D. Each row is one private sale of securities with the running total of its newest notice. The form does not name the series or the investors; rounds are numbered in the order they were filed. A round's details show what its notice does say: accredited and other investors, the smallest investment taken, the exemption claimed, fees, the people named and the brokers paid to sell it.
How it makes money#
What its filings and its own website say, sentence by sentence, each with its source.
M3 Biotechnology, Inc. chose not to state its revenue in its newest notice of a funding round (Jun 2020).
SEC Form D · Jun 2020
The industry group it chose in its notices: Biotechnology.
SEC Form D · Jun 2020
That is all the official record says: M3 Biotechnology, Inc. has not published its revenue in a filing we can read, and no other official source covers it. Revenue figures come from crowdfunding filings (SEC Form C) and from annual reports once a company is listed.
Products and services#
No products or services of M3 Biotechnology, Inc. are on record.
Investors#
5 named in official filings. Open an investor to see everything it has backed.
| Investor | Kind | Amount | Round | Role | Source |
|---|---|---|---|---|---|
| John M. Fluke Jr. | Person | not stated | not stated | Held Series A and A-1 preferred stock, director (Form 3, 2020) | SEC Form 3 |
| Mark James Litton | Person | not stated | not stated | Held Series B preferred stock (Form 3, 2020) | SEC Form 3 |
| Perceptive Advisors LLC | Fund or asset manager | not stated | not stated | Held Series B preferred stock, 10% owner (Form 3, 2020) | SEC Form 3 |
| Perceptive Life Sciences Master Fund LTD | Fund or asset manager | not stated | not stated | Held Series B preferred stock, 10% owner (Form 3, 2020) | SEC Form 3 |
| RTW Investments, LP | Fund or asset manager | not stated | not stated | Held Series B preferred stock, 10% owner (Form 3, 2020) | SEC Form 3 |
Source: SEC Form 3 statements, SEC Form N-PORT fund reports, Wikidata, value.today research. Names come from filings that do name holders: the preferred stock each holder had when the company registered its shares (Form 3), private shares in US mutual funds' portfolio reports (N-PORT), and Wikidata. None ties a name to one funding round, so this list is per company, and it is not complete: the 2 rounds above had up to 73 investors.
Largest shareholders today
Institutions holding LeonaBio, Inc. shares, as of Sep 30, 2026.
- Perceptive Advisors LLC$7 M19.73%
- Acorn Capital Advisors, LLC$4 M12.15%
- ADAR1 Capital Management, LLC$3 M8.25%
- Adage Capital Partners GP, L.L.C.$2 M4.97%
- NEA Management Company, LLC$2 M4.93%
- Commodore Capital LP$2 M4.93%
- TCG Crossover Management, LLC$2 M4.93%
- Spruce Street Capital LP$1 M4.18%
- Kalehua Capital Management LLC$1 M4.18%
- Vanguard Capital Management LLC$1 M2.92%
- Seven Fleet Capital Management LP$1 M1.68%
- Simplify Asset Management Inc.$1 M1.58%
- Propel Bio Management, LLC$1 M1.58%
- Landscape Capital Management, L.L.C.$0 M1.05%
- Citadel Advisors LLC$0 M0.92%
Source: SEC Form 13F holdings reports · as of Sep 30, 2026. Value held and share of the company. All holders are on the company page.
Executives and directors
As the company named them in its notices. Directors of a funded startup are often partners of its investors.
| Name | Role | Named in |
|---|---|---|
| Christina M. Thomson | Executive officer | Jun 2020 |
| Glenna M. Mileson | Executive officer | Jun 2020 |
| Leen Kawas | Executive officer | Jun 2020 |
| Mark M. Litton | Executive officer | Jun 2020 |
| John Fluke | Executive officer | Nov 2017 |
| John M. Fluke, Jr. | Director | Jun 2020 |
| Joseph M. Edelman | Director | Jun 2020 |
| Joseph W. Harding | Director | Jun 2020 |
| Leen Kawas | Director | Jun 2020 |
| Tadataka M. Yamada | Director | Jun 2020 |
| Bruce Montgomery | Director | Nov 2017 |
| John Fluke | Director | Nov 2017 |
| Joseph Harding | Director | Nov 2017 |
| Michael Montgomery | Director | Nov 2017 |
| Leen Kawas | Promoter | Jun 2020 |
Went public since 2020. Its SEC number is that of a company listed on a stock exchange.